Skip to main content

Table 2 Therapeutic, angiographic, and procedural characteristics of the study population

From: Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention

 

Total population (n = 2247)

Lower GA (≤ 14.4%, n = 1133)

Higher GA (> 14.4%, n = 1114)

P value

Medication at admission, n (%)

 ACEI/ARB

500 (22.3)

246 (21.7)

254 (22.8)

0.535

 DAPT

677 (30.1)

348 (30.7)

329 (29.5)

0.542

 Aspirin

1192 (53.0)

598 (52.8)

594 (53.3)

0.797

 P2Y12 inhibitors

718 (32.0)

371 (32.7)

347 (31.1)

0.417

 β-Blocker

496 (22.1)

251 (22.2)

245 (22.0)

0.927

 Statins

691 (30.8)

370 (32.7)

321 (28.8)

0.048

 OHA

400 (17.8)

56 (4.9)

344 (30.9)

 < 0.001

 Insulin

218 (9.7)

13 (1.1)

205 (18.4)

 < 0.001

Medication at discharge, n (%)

 ACEI/ARB

1558 (69.3)

758 (66.9)

800 (71.8)

0.012

 DAPT

2245 (99.9)

1133(100.0)

1112 (99.8)

0.154

 Aspirin

2246 (100.0)

1133 (100.0)

1113(99.9)

0.313

 P2Y12 inhibitors

2247 (100.0)

1133 (100.0)

1114 (100.0)

–

 β-Blocker

2045 (91.0)

1024 (90.4)

1021 (91.7)

0.292

 Statins

2195 (97.7)

1101 (97.2)

1094 (98.2)

0.105

 OHA

396 (17.6)

56 (4.9)

340 (30.5)

 < 0.001

 Insulin

211 (9.4)

12 (1.1)

199 (17.9)

 < 0.001

Angiographic data, n (%)

 LM lesion

102 (4.5)

45 (4.0)

57 (5.1)

0.192

 Multi-vessel lesion

1498 (66.7)

655 (57.8)

843 (75.7)

< 0.001

 In-stent restenosis

124 (5.5)

47 (4.1)

77 (6.9)

0.004

 Chronic total occlusion lesion

295 (13.1)

136 (12.0)

159 (14.3)

0.111

 SYNTAX score

11.0 ± 5.4

10.0 ± 5.1

12.0 ± 5.5

< 0.001

Procedural information

 Target vessel territory, n (%)

  LM

60 (2.7)

31 (2.7)

29 (2.6)

0.845

  LAD

1464 (65.2)

738 (65.1)

726 (65.2)

0.987

  LCX

784 (34.9)

364 (32.1)

420 (37.7)

0.006

  RCA

952 (42.4)

434 (38.3)

518 (46.5)

< 0.001

  Complete revascularization, n (%)

1323 (58.9)

746 (65.8)

577 (51.8)

< 0.001

  Number of DES

2.0 ± 1.3

1.9 ± 1.3

2.0 ± 1.3

0.022

  1. GA glycated albumin, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, DAPT dual antiplatelet therapy, OHA oral hypoglycemic agents, LM left main artery, SYNTAX synergy between PCI with taxus and cardiac surgery LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, DES drug-eluting stent